To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Systemic and intrahepatic… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.

Journal article
Authors Galia Askarieh
Åsa Alsiö
Paolo Pugnale
Francesco Negro
Carlo Ferrari
Avidan U Neumann
Jean-Michel Pawlotsky
Solko W Schalm
Stefan Zeuzem
Gunnar Norkrans
Johan Westin
Jonas Söderholm
Kristoffer Hellstrand
Martin Lagging
Published in Hepatology
Volume 51
Issue 5
Pages 1523-1530
ISSN 1527-3350
Publication year 2010
Published at Institute of Biomedicine, Department of Infectious Medicine
Pages 1523-1530
Language en
Keywords Adult, Chemokine CXCL10, blood, metabolism, Drug Therapy, Combination, Female, Hepacivirus, genetics, Hepatitis C, Chronic, drug therapy, genetics, Humans, Interferon Alfa-2a, administration & dosage, therapeutic use, Liver, metabolism, Male, Middle Aged, Polyethylene Glycols, administration & dosage, therapeutic use, Prognosis, RNA, Viral, genetics, metabolism, Ribavirin, administration & dosage, therapeutic use
Subject categories Microbiology in the medical area


High systemic levels of interferon-gamma-inducible protein 10 kDa (IP-10) at onset of combination therapy for chronic hepatitis C virus (HCV) infection predict poor outcome, but details regarding the impact of IP-10 on the reduction of HCV RNA during therapy remain unclear. In the present study, we correlated pretreatment levels of IP-10 in liver biopsies (n = 73) and plasma (n = 265) with HCV RNA throughout therapy within a phase III treatment trial (DITTO-HCV). Low levels of plasma or intrahepatic IP-10 were strongly associated with a pronounced reduction of HCV RNA during the first 24 hours of treatment in all patients (P < 0.0001 and P = 0.002, respectively) as well as when patients were grouped as genotype 1 or 4 (P = 0.0008 and P = 0.01) and 2 or 3 (P = 0.002, and P = 0.02). Low plasma levels of IP-10 also were predictive of the absolute reduction of HCV RNA (P < 0.0001) and the maximum reduction of HCV RNA in the first 4 days of treatment (P < 0.0001) as well as sustained virological response (genotype 1/4; P < 0.0001). To corroborate the relationship between early viral decline and IP-10, pretreatment plasma samples from an independent phase IV trial for HCV genotypes 2/3 (NORDynamIC trial; n = 382) were analyzed. The results confirmed an association between IP-10 and the immediate reduction of HCV RNA in response to therapy (P = 0.006). In contrast, pretreatment levels of IP-10 in liver or in plasma did not affect the decline of HCV RNA between days 8 and 29, i.e., the second-phase decline, or later time points in any of these cohorts. CONCLUSION: In patients with chronic hepatitis C, low levels of intrahepatic and systemic IP-10 predict a favorable first-phase decline of HCV RNA during therapy with pegylated interferon and ribavirin for genotypes of HCV.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?